Search
Menu
AdTech Ceramics - Ceramic Packages 1-24 LB

Viralytics strengthens portfolio

Facebook X LinkedIn Email
In Sydney, Australia, Viralytics Ltd. has received a US patent for the use of Echoviruses, including the proprietary Evatak formulation of Echovirus Type 1, to treat all cancers expressing the integrin a2b1 molecule. Included are ovarian, prostate and gastric forms, all of which express high levels of the molecule on their surfaces. The patent provides the company with the exclusive use of the viruses in this manner until 2023, and it strengthens Viralytics’ intellectual property portfolio.Read full article

Related content from Photonics Media



    Articles


    White Papers


    Webinars


    Photonics Dictionary Terms


    Media


    Photonics Buyers' Guide Categories
    Published: June 2009
    cancermoleculePatent NewsSlices from the Breadboardvirus

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.